EmeraMed Overview

  • Founded
  • 2007

  • Status
  • Private

  • Employees
  • 7

  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $274K

EmeraMed General Information


Operator of a biotechnology firm intended to develop the lipophilic blood-brain-barrier passing antioxidant emeramide. The company focuses on chelating free iron as well as many heavy metals, such as mercury and lead, which would otherwise create free radicals, enabling healthcare providers to restore normal function to the mitochondria and improve overall health.

Contact Information

Formerly Known As
Ermes Medical Co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Trinity House, Charleston Road
  • Ranelagh
  • Dublin 6
  • Ireland
+353 (092) 000 000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EmeraMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 15-Nov-2016 $274K 00.000 Completed Clinical Trials - Phase 2
1. Seed Round 17-Jun-2016 00.000 00.000 Completed Clinical Trials - Phase 2
To view EmeraMed’s complete valuation and funding history, request access »

EmeraMed Patents

EmeraMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202213577-D0 New pharmaceutical use Pending 15-Sep-2022
GB-202212071-D0 New medical uses Pending 18-Aug-2022
GB-202113078-D0 New pharmaceutical use Inactive 14-Sep-2021
GB-202111911-D0 New medical uses Inactive 19-Aug-2021
GB-202014420-D0 New pharmaceutical use Inactive 14-Sep-2020
To view EmeraMed’s complete patent history, request access »

EmeraMed Executive Team (3)

Name Title Board Seat Contact Info
Boyd Haley Ph.D Founder, Chief Executive Officer, Chief Scientist & Board Member
Ragnar Klingberg Executive Officer & Board Member
You’re viewing 2 of 3 executive team members. Get the full list »

EmeraMed Board Members (5)

Name Representing Role Since
Boyd Haley Ph.D EmeraMed Founder, Chief Executive Officer, Chief Scientist & Board Member 000 0000
David Kennedy Self Board Member 000 0000
Kathryn Wachsman JD EmeraMed Board Member 000 0000
Paul Reicherter MD EmeraMed Board Member 000 0000
Ragnar Klingberg EmeraMed Executive Officer & Board Member 000 0000
To view EmeraMed’s complete board members history, request access »

EmeraMed Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EmeraMed Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 0000000 01-Jul-2014 0000000000 Biotechnology 0000 0000
To view EmeraMed’s complete acquisitions history, request access »